EXELIXIS

At Exelixis, we recognize that many racial and ethnic communities are underrepresented in clinical research. Inclusive clinical trial design improves the quality and equity of treatments for key affected populations. Exelixis is dedicated to identifying, discussing, and implementing solutions that will increase the number of patients from underrepresented populations in all phases of clinical trials supported and sponsored by the company... Our mission is to make progress towards racial equity in clinical research. Let's make a difference for underrepresented patients... Learn about the STELLAR trials program that is investigating the use of zanzalintinib (XL092) in various tumor types. Uses and/or compounds described here are investigational. Safety and efficacy have not been established.

Also known as: Exelixis, Inc.